Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32245
Title: A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): Mutational analysis, phenotypic variability and treatment challenges.
Authors: Rodda C.P.;Thakker R.V.;Christie P.;Curley A.;Burren C.P.
Institution: (Burren) Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, United Bristol Healthcare NHS Trust, Bristol, Avon BS6 5TU, United Kingdom (Curley, Christie, Thakker) Academic Endocrine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxfordshire, United Kingdom (Rodda) Department of Biochemistry and Microbiology, Monash University, Monash Medical Centre, Clayton, Vic., Australia
Issue Date: 17-Oct-2012
Copyright year: 2005
Publisher: Walter de Gruyter and Co. (Genthiner Strasse 13, Berlin D-10785, Germany)
Place of publication: Israel
Publication information: Journal of Pediatric Endocrinology and Metabolism. 18 (7) (pp 689-699), 2005. Date of Publication: July 2005.
Abstract: Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is an intriguing syndrome, in which activating mutations of the calcium sensing receptor (CaSR) have recently been recognised. We describe a kindred with seven affected individuals across three generations, including patients affected in the first decade of life. Age at diagnosis varied from birth to 50 years. Affected members had hypocalcaemia (1.53-1.85 mmol/l), hypercalciuria, low but detectable parathyroid hormone (PTH) and hypomagnesaemia. Four of seven affected individuals were symptomatic (seizures, abdominal pains and paraesthesias), unrelated to severity of hypocalcaemia. Additional complications include nephrocalcinosis (n = 3) and basal ganglia calcification, identified by CT scanning in all five individuals. Symptomatic individuals were treated with calcium and calcitriol to reduce the risk of hypocalcaemic seizures. DNA sequence analysis, identified a mutation in exon 3, codon 129 (TGC->TAC) of the CaSR gene of seven affected family members, resulting in loss of a conserved, cysteine residue, potentially disrupting CaSR receptor dimerisation. Thus, a novel mutation was identified in this family, who demonstrate variability of ADHH phenotype and also illustrate the complexities of clinical management. Optimal management of ADHH is difficult and we recommend judicious treatment to avoid an increased risk of nephrocalcinosis. © Freund Publishing House Ltd., London.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1515/JPEM.2005.18.7.689
PubMed URL: 16128246 [http://www.ncbi.nlm.nih.gov/pubmed/?term=16128246]
ISSN: 0334-018X
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/32245
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

12
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.